About US
Contact us
-
Activist investor Starboard sets its sights on J&J spinout Kenvue: WSJActivist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has Johnson & Johnson’s consumer health spinout Kenvue in its sights. The invest2024/9/24
-
Takeda details another round of layoffs in Massachusetts as restructuring drive rolls onFollowing a series of layoff rounds this year, Takeda is once again pruning its headcount in the Bay State. Takeda is laying off dozens of employees in Massachusetts, according to a Worker Adjustment2024/9/24
-
ICER raises cost-effective price for Pfizer's ATTR drug in final analysis but still calls for hefty discountAfter calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S. drug cost watchdog has provided a final analysis that includes a smaller—y2024/9/30
-
Sanofi in 'exclusive negotiations' to sell 50% stake in €16B consumer health unit OpellaSanofi is now in“exclusive negotiations”with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French g2024/10/10
-
CDMO Samsung Biologics bags $1.2B production contract, bringing total 2024 deal value to $3.3B+With multiple high-profile production pacts already in the books for 2024, CDMO Samsung Biologics has hooked another big one. Samsung has locked down a $1.2 billion contract with an unnamed Asia-base2024/10/10
-
DOJ challenges Johnson & Johnson's talc bankruptcy attempt in TexasWith Johnson & Johnson sweetening the pot and mustering up the support of 83% of those who claim that the company’s talc products caused their cancer, it hadappearedthat the sides were speeding t2024/10/15
-
Pfizer lays off 75 more workers in North Carolina in wake of late-stage DMD trial failPfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. The layoffs come three months after the company axed 150 positions in Sanford following a high-prof2024/10/15
-
Amid geopolitical tensions, Legend sheds Genscript as its majority shareholderLegend Biotech has managed to remove Genscript Biotech as its majority shareholder, just as the former parent’s Chinese background falls under a U.S. biosecurity microscope. After a financial maneuve2024/10/17
-
Red light, green light: England's NICE not sold on Lilly's Kisunla despite UK approvalEli Lilly’s Alzheimer’s disease offering Kinsunla is poised to face a tough road ahead in the U.K. While the region’s Medicines and Healthcare products Regulatory Agency (MHRA) signed off on an appro2024/10/17
-
Roche's Vabysmo will rise above Eylea biosim threat, exec says, as DMD gene therapy Elevidys delivers sales surpriseBy squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. But will the potential imminent launch of a copycat to Eylea stifle Vabysmo’s market e2024/10/22